3_Direct to consumer advertising in oncology - Abel et al.

3_Direct to - Abel Penson Joffe et al 219 pharmaceutical companies aims in sponsoring directto-consumer advertising such that this sort of unbiased

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
Abel, Penson, Joffe et al. 219 www.TheOncologist.com pharmaceutical companies’ aims in sponsoring direct- to-consumer advertising, such that this sort of unbiased advertising fundamentally cannot happen. Reconciling the competing issues would be impossible because the parties are too conflicted, and the answer then would be to not allow direct-to-consumer advertising at all. Direct-to-consumer advertising certainly has the ability to change the nature of the relationships that caregivers have with their patients, and vice versa. That is true of medical information that comes from any source, such as information available on the internet, from advocacy groups, and from professional organizations. Any of this information could potentially change the quality of that relation- ship and strengthen the position of patients and families. From what I have seen of direct-to-con- sumer advertising, a lot of the drugs that are promoted seem to be lifestyle drugs, or so-called “me-too” drugs. I have not seen a lot of advertising for chemotherapy, although we are start- ing to see more advertising for supportive drugs that are relevant to oncology. I have a hypothesis about which types of oncology drugs are most likely to be advertised directly to the consumer. I think they are less likely to
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 10/10/2010 for the course ENG 000121 taught by Professor Mcgrand during the Spring '10 term at Cornell University (Engineering School).

Ask a homework question - tutors are online